journal article·2026-01Open access

Dysregulation of CircZNF79(5) Modulates YBX1 Stability and Selective Autophagy to Drive Hepatocellular Carcinoma Progression

Xueqiang Guo, Lingling Xi, Yukun Liu, Wenbao Lv, Tianzi Li, Andong Ju, Zhenlin Fan, Yaping Shen, Zhuang Qian, Weiyun Wang, Zhuo Liang, Wenjuan Song, Kaiwen Chang, Shuangping Ma, Junhe Zhang, Tao Han, Kun You, Cunshuan Xu, Lei Wang, Weisheng Guo, Wenjie Ren

Advanced Science· Volume 13· Issue 6

Abstract

Abstract Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy with limited therapeutic options. Circular RNAs (circRNAs) have emerged as critical regulators in various cancers, including HCC, but their roles in HCC progression remain largely unexplored. Here, the role of circZNF79(5) in HCC progression and its underlying mechanisms is investigated. CircZNF79(5) expression in HCC tissues, cell lines and the serum exosomes is analyzed using qRT‐PCR and FISH, and evaluated its effects on cell proliferation, migration, invasion and apoptosis using CCK8, colony formation, EdU, Transwell and Flow cytometry. CircZNF79(5)’s is verified to be upregulated in HCC, and found that it can promote HCC cells proliferation, migration and invasion, while inhibiting the apoptosis. Mechanistically, circZNF79(5) is found to stabilizes the oncogenic protein YBX1 by recruiting BRCC36, a K63 chain deubiquitinating enzyme, thereby preventing YBX1 from p62‐mediated selective autophagic degradation via the AMPK/mTOR signaling pathway. In vivo studies using subcutaneous and orthotopic tumor models confirmed that circZNF79(5) knockdown reduced tumor growth and YBX1 expression. The findings reveal a novel mechanism by which circZNF79(5) promotes HCC progression through YBX1 stabilization and selective autophagy regulation, highlighting the circZNF79(5)‐YBX1‐BRCC36 axis as a potential therapeutic target for HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Circular RNAs in diseases · Cancer-related molecular mechanisms research · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The First Affiliated Hospital of Xinxiang Medical University Institutes of Health Central Plain The Third Affiliated Hospital of Xinxiang Medical University Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy Xinxiang Key Laboratory of Molecular Oncology Xinxiang Medical University Xinxiang 453003 P. R. China

Clinical Medical Center of Tissue Engineering and Regeneration Xinxiang Medical University Xinxiang 453003 P. R. China

State Key Laboratory of Antiviral Drugs Pingyuan Laboratory Henan Normal University Xinxiang 453007 P. R. China

Abdominal Surgical Oncology Xinxiang Central Hospital Institute of the Fourth Affiliated Hospital of Xinxiang Medical University Xinxiang 453003 P. R. China

The First Affiliated Hospital of Xinxiang Medical University Xinxiang Medical University Xinxiang 453003 P. R. China

College of Life Science Henan Normal University Xinxiang 453003 P. R. China

Department of Minimally Invasive Interventional Radiology The Second Affiliated Hospital School of Biomedical Engineering Guangzhou Medical University Guangzhou 510260 P. R. China

References (39)

Show source-provided references
1. 10.1002/hep.2096910.1002/hep.20969 ↗
2. 10.1016/j.canlet.2023.21644210.1016/j.canlet.2023.216442 ↗
3. 10.1073/pnas.73.11.385210.1073/pnas.73.11.3852 ↗
4. 10.1038/nature1192810.1038/nature11928 ↗
5. 10.1038/323558a010.1038/323558a0 ↗
6. 10.1038/s41571-021-00585-y10.1038/s41571-021-00585-y ↗
7. 10.1186/s12943-020-01286-310.1186/s12943-020-01286-3 ↗
8. 10.1002/hep.3106810.1002/hep.31068 ↗
9. 10.1038/s41419-023-05989-510.1038/s41419-023-05989-5 ↗
10. 10.1038/s41586-024-07060-510.1038/s41586-024-07060-5 ↗
11. 10.1073/pnas.221513212010.1073/pnas.2215132120 ↗
12. 10.1002/ctm2.145110.1002/ctm2.1451 ↗
13. 10.1002/advs.20230590210.1002/advs.202305902 ↗
14. 10.1038/s41392-023-01561-x10.1038/s41392-023-01561-x ↗
15. 10.1038/s41586-023-06834-710.1038/s41586-023-06834-7 ↗
16. 10.1016/j.ymthe.2023.11.01710.1016/j.ymthe.2023.11.017 ↗
17. 10.1038/d41586-024-03683-w10.1038/d41586-024-03683-w ↗
18. 10.1038/s41556-022-01066-910.1038/s41556-022-01066-9 ↗
19. 10.1038/s41420-021-00710-x10.1038/s41420-021-00710-x ↗
20. 10.1073/pnas.222029612010.1073/pnas.2220296120 ↗
21. 10.1016/j.ccell.2015.04.00310.1016/j.ccell.2015.04.003 ↗
22. 10.1073/pnas.211345411910.1073/pnas.2113454119 ↗
23. 10.1038/ncb232910.1038/ncb2329 ↗
24. 10.1186/s12943-023-01719-910.1186/s12943-023-01719-9 ↗
25. 10.1038/s41419-021-03626-710.1038/s41419-021-03626-7 ↗
26. 10.1002/advs.20241432510.1002/advs.202414325 ↗
27. 10.1002/advs.20241059110.1002/advs.202410591 ↗
28. 10.1002/advs.20241678410.1002/advs.202416784 ↗
29. 10.3748/wjg.v27.i28.466710.3748/wjg.v27.i28.4667 ↗
30. 10.1038/s12276-023-01108-810.1038/s12276-023-01108-8 ↗
31. 10.1038/s41392-020-00375-510.1038/s41392-020-00375-5 ↗
32. 10.1016/j.canlet.2023.21649510.1016/j.canlet.2023.216495 ↗
33. 10.1016/j.omtn.2020.10.02510.1016/j.omtn.2020.10.025 ↗
34. 10.1002/hep.3129310.1002/hep.31293 ↗
35. 10.1038/s41580-022-00542-210.1038/s41580-022-00542-2 ↗
36. 10.1056/NEJMra202277410.1056/NEJMra2022774 ↗
37. 10.1038/cr.2013.16110.1038/cr.2013.161 ↗
38. 10.1016/j.molcel.2019.06.00210.1016/j.molcel.2019.06.002 ↗
39. 10.1002/advs.20230426310.1002/advs.202304263 ↗